Literature DB >> 23568249

Extended lymphadenectomy in pancreatic cancer is crucial.

Tsutomu Fujii1.   

Abstract

Lymph node metastasis is considered one of the most significant factors associated with postoperative prognosis in patients with pancreatic cancer. Some prospective studies found no significant differences in survival between patients who underwent pancreatic cancer surgery with extended lymphadenectomy and those who underwent surgery with standard lymphadenectomy. However, recent reports, such as those describing the significance of the metastatic to examined lymph node ratio, suggest the need for some degree of lymphadenectomy. This review describes the findings of published studies and discusses the usefulness of LN dissection in patients with pancreatic cancer.

Entities:  

Mesh:

Year:  2013        PMID: 23568249     DOI: 10.1007/s00268-013-2039-0

Source DB:  PubMed          Journal:  World J Surg        ISSN: 0364-2313            Impact factor:   3.352


  38 in total

1.  Prognostic impact of para-aortic lymph node metastasis in pancreatic ductal adenocarcinoma.

Authors:  Yoshiaki Murakami; Kenichiro Uemura; Takeshi Sudo; Yasushi Hashimoto; Yoshio Yuasa; Taijiro Sueda
Journal:  World J Surg       Date:  2010-08       Impact factor: 3.352

2.  Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: a randomized controlled trial.

Authors:  Helmut Oettle; Stefan Post; Peter Neuhaus; Klaus Gellert; Jan Langrehr; Karsten Ridwelski; Harald Schramm; Joerg Fahlke; Carl Zuelke; Christof Burkart; Klaus Gutberlet; Erika Kettner; Harald Schmalenberg; Karin Weigang-Koehler; Wolf-Otto Bechstein; Marco Niedergethmann; Ingo Schmidt-Wolf; Lars Roll; Bernd Doerken; Hanno Riess
Journal:  JAMA       Date:  2007-01-17       Impact factor: 56.272

Review 3.  Vascular anatomy of the pancreas and clinical applications.

Authors:  K Ibukuro
Journal:  Int J Gastrointest Cancer       Date:  2001

Review 4.  Locoregional dissemination and extended lymphadenectomy in pancreatic cancer.

Authors:  L Fernández-Cruz; C Johnson; C Dervenis
Journal:  Dig Surg       Date:  1999       Impact factor: 2.588

5.  The role of extended radical operation for pancreatic cancer.

Authors:  A Nakao; T Kaneko; S Takeda; S Inoue; A Harada; S Nomoto; T Ekmel; K Yamashita; T Hatsuno
Journal:  Hepatogastroenterology       Date:  2001 Jul-Aug

6.  Extended radical resection versus standard resection for pancreatic cancer: the rationale for extended radical resection.

Authors:  Akimasa Nakao; Shin Takeda; Mitsuru Sakai; Tetsuya Kaneko; Soichiro Inoue; Hiroyuki Sugimoto; Naohito Kanazumi
Journal:  Pancreas       Date:  2004-04       Impact factor: 3.327

7.  Standard versus extended lymphadenectomy associated with pancreatoduodenectomy in the surgical treatment of adenocarcinoma of the head of the pancreas: a multicenter, prospective, randomized study. Lymphadenectomy Study Group.

Authors:  S Pedrazzoli; V DiCarlo; R Dionigi; F Mosca; P Pederzoli; C Pasquali; G Klöppel; K Dhaene; F Michelassi
Journal:  Ann Surg       Date:  1998-10       Impact factor: 12.969

8.  The ratio of metastatic to examined lymph nodes is a powerful independent prognostic factor in rectal cancer.

Authors:  Frédérique Peschaud; Peschaud Frédérique; Stéphane Benoist; Benoist Stéphane; Catherine Julié; Julié Catherine; Alain Beauchet; Beauchet Alain; Christophe Penna; Penna Christophe; Philippe Rougier; Rougier Philippe; Bernard Nordlinger
Journal:  Ann Surg       Date:  2008-12       Impact factor: 12.969

9.  Prognostic factors after resection of pancreatic cancer.

Authors:  Michio Ueda; Itaru Endo; Masayuki Nakashima; Yuta Minami; Kazuhisa Takeda; Kenichi Matsuo; Yasuhiko Nagano; Kuniya Tanaka; Yasushi Ichikawa; Shinji Togo; Chikara Kunisaki; Hiroshi Shimada
Journal:  World J Surg       Date:  2009-01       Impact factor: 3.352

10.  Pancreaticoduodenectomy with or without distal gastrectomy and extended retroperitoneal lymphadenectomy for periampullary adenocarcinoma, part 2: randomized controlled trial evaluating survival, morbidity, and mortality.

Authors:  Charles J Yeo; John L Cameron; Keith D Lillemoe; Taylor A Sohn; Kurtis A Campbell; Patricia K Sauter; JoAnn Coleman; Ross A Abrams; Ralph H Hruban
Journal:  Ann Surg       Date:  2002-09       Impact factor: 12.969

View more
  5 in total

Review 1.  The lymphatic system and pancreatic cancer.

Authors:  Darci M Fink; Maria M Steele; Michael A Hollingsworth
Journal:  Cancer Lett       Date:  2015-12-29       Impact factor: 8.679

Review 2.  Mesopancreas: A boundless structure, namely the rationale for dissection of the paraaortic area in pancreaticoduodenectomy for pancreatic head carcinoma.

Authors:  Nadia Peparini
Journal:  World J Gastroenterol       Date:  2015-03-14       Impact factor: 5.742

3.  Analysis on survival and prognostic factors in patients with resectable pancreatic adenocarcinoma.

Authors:  Rong Lin; Chao-Qun Han; Wei-Jun Wang; Jun Liu; Wei Qian; Zhen Ding; Xiao-Hua Hou
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2017-08-08

Review 4.  Local and systemic immunosuppression in pancreatic cancer: Targeting the stalwarts in tumor's arsenal.

Authors:  Clara S Mundry; Kirsten C Eberle; Pankaj K Singh; Michael A Hollingsworth; Kamiya Mehla
Journal:  Biochim Biophys Acta Rev Cancer       Date:  2020-06-21       Impact factor: 10.680

5.  Lymph node ratio is an independent prognostic factor for patients after resection of pancreatic cancer.

Authors:  Han-xiang Zhan; Jian-wei Xu; Lei Wang; Guang-yong Zhang; San-yuan Hu
Journal:  World J Surg Oncol       Date:  2015-03-13       Impact factor: 2.754

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.